Cobra Biologics has entered a collaboration with the Centre for Process Innovation (CPI), a UK-based technology innovation centre and GE Healthcare Life Sciences.    The three-way partnership, funded by a £570K Innovate UK grant, aims to increase the robustness and reduce costs for the manufacturing of adeno-associated virus (AAV) vectors, a delivery vehicle used for emerging gene therapy treatments. The gene therapy area has been developing rapidly and while only a small number of treat...